Citation Impact
Citing Papers
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
2016
Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy
2015
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
2021
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
Microenvironmental regulation of tumour angiogenesis
2017
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Targeting Vascular Pericytes in Hypoxic Tumors Increases Lung Metastasis via Angiopoietin-2
2015
Engineering precision nanoparticles for drug delivery
2020 Standout
The application of nanotechnology in immune checkpoint blockade for cancer treatment
2018
Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
2015
Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies
2022
Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification
2017
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling
2016
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
Vessel co-option in cancer
2019
Intravital imaging to study cancer progression and metastasis
2022
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
The Immune Microenvironment and Cancer Metastasis
2019
Macrophages in immunoregulation and therapeutics
2023 Standout
Hepatocellular carcinoma
2021 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
2021
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
2020
A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation
2018
Delivery technologies for cancer immunotherapy
2019 Standout
Ten years of anti-vascular endothelial growth factor therapy
2016
From Krebs to clinic: glutamine metabolism to cancer therapy
2016 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
2018
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Dormant tumour cells, their niches and the influence of immunity
2018
Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity
2022
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Oxidative Stress in Cancer
2020 Standout
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
Immunotherapy for Breast Cancer: Current and Future Strategies
2017
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
2017
Therapeutic targeting of the angiopoietin–TIE pathway
2017
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
2017
Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment
2021
Antiangiogenic therapy in oncology: current status and future directions
2016
Targeting Macrophages in Cancer: From Bench to Bedside
2018
Neutrophils in cancer: neutral no more
2016 Standout
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
2018
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming
2021
Hepatocellular carcinoma
2022 Standout
Macrophages as tools and targets in cancer therapy
2022
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges
2021
The Intersection between Tumor Angiogenesis and Immune Suppression
2019
Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials
2021
Breast Cancer Statistics, 2022
2022 Standout
Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions
2019
Diversity, Mechanisms, and Significance of Macrophage Plasticity
2019 Standout
Therapeutic Targeting of the Tumor Microenvironment
2021
Anti-Angiogenics: Current Situation and Future Perspectives
2018
Inositol Polyphosphate Multikinase Inhibits Angiogenesis via Inositol Pentakisphosphate-Induced HIF-1α Degradation
2017 StandoutNobel
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
2019
Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
2018
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Biomimetic and Self-Assembled Nanoclusters Targeting β-Catenin for Potent Anticancer Therapy and Enhanced Immunotherapy
2019
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
2017
Tumor-associated macrophages promote intratumoral conversion of conventional CD4 + T cells into regulatory T cells via PD-1 signalling
2022
Targeting CXCR4-dependent immunosuppressive Ly6C low monocytes improves antiangiogenic therapy in colorectal cancer
2017
Works of Ece Kadioglu being referenced
The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors
2017
Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
2014
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models
2021
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
2017